Physician profile
Rosalyn A Thomas
NPI 1609209519
$1,239.00
in general payments reported to CMS, 2019-2025
16 companies · $863 in 2025
The $863 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.17 · 2023: $14.02 · 2024: $340 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,216.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $266.62 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $263.12 | 2024-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $140.96 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $119.61 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $90.98 | 2025 | |
| Boston Scientific Corporation | $82.21 | 2022-2025 | General - Pain Management |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.74 | 2025 | Jardiance |
| Medtronic, INC. | $37.22 | 2025 | Interstim |
| Pfizer INC. | $34.32 | 2024-2025 | |
| Exact Sciences Corporation | $32.03 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $28.75 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $22.51 | 2024 | Opsumit, Uptravi |
| Astellas Pharma US INC | $22.14 | 2025 | Veozah |
| Amgen INC. | $20.66 | 2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.13 | 2024 | Xifaxan |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.00 | 2024 | Gardasil 9, Gardasil, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosalyn Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.